Article Information
History
- June 1, 2022.
Article Versions
- You are currently viewing Version 1 of this article (June 1, 2022 - 16:54).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Amen Ben Hamida1,2,*,
- Myrna Charles2,3,
- Christopher Murrill2,4,
- Olga Henao1,2 and
- Kathleen Gallagher1,2
- 1Division of Global Health Protection, U.S. CDC, Atlanta, GA, USA
- 2COVID-19 International Task Force, U.S. CDC, Atlanta, GA, USA
- 3Influenza Division, U.S CDC, Atlanta, GA, USA
- 4Global Immunization Division, U.S. CDC, Atlanta, GA, USA
- ↵*Corresponding author:
ABenHamida{at}cdc.gov (ABH)
Posted June 01, 2022.
U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
